NASDAQ:VSAR - Versartis Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$1.19 -0.02 (-1.65 %)
(As of 11/13/2018 04:00 PM ET)
Previous Close$1.21
Today's Range$1.1802 - $1.30
52-Week Range$1.14 - $2.76
Volume349,963 shs
Average Volume479,436 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Versartis, Inc. operates as an endocrine-focused biopharmaceutical company in the United States. It is developing somavaratan, a long-acting recombinant human growth hormone for the treatment of growth hormone deficiency. The company was founded in 2008 and is headquartered in Menlo Park, California.

Receive VSAR News and Ratings via Email

Sign-up to receive the latest news and ratings for VSAR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VSAR
Previous Symbol
CUSIPN/A
Phone650-963-8580

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees10
Outstanding SharesN/A
Market Cap$0.00
OptionableOptionable

Versartis (NASDAQ:VSAR) Frequently Asked Questions

What is Versartis' stock symbol?

Versartis trades on the NASDAQ under the ticker symbol "VSAR."

How were Versartis' earnings last quarter?

Versartis Inc (NASDAQ:VSAR) issued its quarterly earnings results on Tuesday, August, 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating the consensus estimate of ($0.96) by $0.69. View Versartis' Earnings History.

What price target have analysts set for VSAR?

1 brokerages have issued 12-month target prices for Versartis' shares. Their forecasts range from $5.00 to $5.00. On average, they anticipate Versartis' stock price to reach $5.00 in the next year. This suggests a possible upside of 320.2% from the stock's current price. View Analyst Price Targets for Versartis.

What is the consensus analysts' recommendation for Versartis?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Versartis in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Versartis.

Has Versartis been receiving favorable news coverage?

Media headlines about VSAR stock have been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Versartis earned a news impact score of 0.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 8.0 out of 10, indicating that recent press coverage is very likely to have an effect on the company's share price in the near future.

Who are some of Versartis' key competitors?

Who are Versartis' key executives?

Versartis' management team includes the folowing people:
  • Mr. Jay P. Shepard, Pres, CEO & Director (Age 60)
  • Ms. Tracy M. Woody, Chief Commercial Officer (Age 48)
  • Dr. Jeffrey L. Cleland, Co-Founder (Age 53)
  • Dr. Joshua Silverman Ph.D., Co-Founder
  • Mr. Kevin Haas, VP of Fin. (Age 53)

Who are Versartis' major shareholders?

Versartis' stock is owned by many different of institutional and retail investors. Top institutional investors include Dimensional Fund Advisors LP (0.00%) and GSA Capital Partners LLP (0.00%). Company insiders that own Versartis stock include Colin Hislop, Edmon R Jennings, Jay S Stout, Jay Shepard, Joshua T Brumm, Kevin Haas, Life Sciences Maste Perceptive, Paul Westberg, Perceptive Advisors Llc, Shahzad Malik, Shane Ward, Srinivas Akkaraju and Tracy M Woody. View Institutional Ownership Trends for Versartis.

Which institutional investors are selling Versartis stock?

VSAR stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP. Company insiders that have sold Versartis company stock in the last year include Jay S Stout, Jay Shepard, Kevin Haas, Paul Westberg and Tracy M Woody. View Insider Buying and Selling for Versartis.

Which institutional investors are buying Versartis stock?

VSAR stock was purchased by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP. Company insiders that have bought Versartis stock in the last two years include Perceptive Advisors Llc and Srinivas Akkaraju. View Insider Buying and Selling for Versartis.

How do I buy shares of Versartis?

Shares of VSAR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Versartis' stock price today?

One share of VSAR stock can currently be purchased for approximately $1.19.

What is Versartis' official website?

The official website for Versartis is http://www.versartis.com.

How can I contact Versartis?

Versartis' mailing address is 1020 Marsh Rd, Menlo Park CA, 94025. The biopharmaceutical company can be reached via phone at 650-963-8580 or via email at [email protected]


MarketBeat Community Rating for Versartis (NASDAQ VSAR)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  270 (Vote Outperform)
Underperform Votes:  214 (Vote Underperform)
Total Votes:  484
MarketBeat's community ratings are surveys of what our community members think about Versartis and other stocks. Vote "Outperform" if you believe VSAR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSAR will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/13/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel